ZELIG ESHAR ADOPTIVE T-CELL THERAPY YOUNG INVESTIGATOR AWARD

This award is generously supported in the name of Zelig Eshar, it recognises the two best abstracts in the field of adoptive T-cell therapy and the impact of research carried out by early career researchers (Under 40). This award will be handed out at the ESGCT congress for the next 10 years.

The awardee will present a talk at the ESGCT Annual Congress.

Zelig Eshar winner of the ESGCT Outstanding Achievement award 2013. More a ou Zelig Eshar here

Eligibility Criteria

1. Nominees must be a member of the ESGCT

2. All young investigators under 40 years old

3. Extension of this period may be allowed in case of eligible career breaks: maternity or paternity leave (1 year per child born after the PhD award); leave taken for long-term illness or national service; leave taken for unavoidable statutory reasons (e.g. clinical qualification). The cumulative eligibility period should not surpass 5 years following the award of the first PhD, unless the Board agrees they are the best candidate for the award.

4. For medical doctors, date of the clinical speciality completion is the time reference for calculation of the eligibility time-window. For MD and PhD, date of the PhD award takes precedence in the calculation of the eligibility time-window.

5. Winner must submit an abstract to the ESGCT congress

   
   

Nomination and Selection Process

Applicants must have submitted an abstract to the ESGCT congress.  The 2 winners of this award will be selected from the highest scoring abstracts in the field of T-Cell adoptive therapies.  The final selection will be made by the Zelig Eshar award scientific committee.

AWARD VALUE: 2 awards of €2500

Zelig Eshar adoptive T-Cell therapy young investigator award winners

2026 -